Since the emergence of severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, and the end of March 2020, there have been almost 1,500,000 cases of COVID-19 and more than 90,000 deaths worldwide. There are currently no FDA-approved vaccines or small molecule therapeutics for the treatment and prophylaxis of COVID-19, underscoring the need for effective countermeasures to halt the growing pandemic. The presentation will briefly review coronaviruses, their life cycle, and state-of-the art progress in the development of vaccines and immunotherapeutics, as well as the use of repurposed drugs. Lastly, progress by our research group related to the discovery of inhibitors of SARS-CoV-2 3CL protease, an enzyme essential for viral replication, will also be discussed briefly.